Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although cannabis use disorder is strongly related to schizophrenia and treatment of patients with double diagnosis provides serious problem, specific pharmacological, molecular and therapeutical data on this subgroup are poorly available. In this paper we present a critical review on psychopharmacological boundaries of schizophrenia with concurrent cannabis use. The relevant data available in the literature suggest that a weaker compliance, poorer therapy response and higher sensitivity for extrapyramidal side effects are key features of schizophrenia and comorbid cannabis use disorder and represent a clinical challenge. Because of paucity of available research in the field there is not enough evidence to clearly depict the exact psychopharmacological profile of cannabis related schizophrenia. Further investigations are needed to assess phenotypic characteristics of this entity and to tailor effective treatment options accordingly.

Original languageEnglish
Pages (from-to)4890-4896
Number of pages7
JournalCurrent Pharmaceutical Design
Volume18
Issue number32
Publication statusPublished - 2012

Fingerprint

Cannabis
Schizophrenia
Compliance
Therapeutics
Pharmacology
Research

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder : a critical review. / Lazáry, J.

In: Current Pharmaceutical Design, Vol. 18, No. 32, 2012, p. 4890-4896.

Research output: Contribution to journalArticle

@article{976a0027c3cd4d27b2ed70e038ebc780,
title = "Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review.",
abstract = "Although cannabis use disorder is strongly related to schizophrenia and treatment of patients with double diagnosis provides serious problem, specific pharmacological, molecular and therapeutical data on this subgroup are poorly available. In this paper we present a critical review on psychopharmacological boundaries of schizophrenia with concurrent cannabis use. The relevant data available in the literature suggest that a weaker compliance, poorer therapy response and higher sensitivity for extrapyramidal side effects are key features of schizophrenia and comorbid cannabis use disorder and represent a clinical challenge. Because of paucity of available research in the field there is not enough evidence to clearly depict the exact psychopharmacological profile of cannabis related schizophrenia. Further investigations are needed to assess phenotypic characteristics of this entity and to tailor effective treatment options accordingly.",
author = "J. Laz{\'a}ry",
year = "2012",
language = "English",
volume = "18",
pages = "4890--4896",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "32",

}

TY - JOUR

T1 - Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder

T2 - a critical review.

AU - Lazáry, J.

PY - 2012

Y1 - 2012

N2 - Although cannabis use disorder is strongly related to schizophrenia and treatment of patients with double diagnosis provides serious problem, specific pharmacological, molecular and therapeutical data on this subgroup are poorly available. In this paper we present a critical review on psychopharmacological boundaries of schizophrenia with concurrent cannabis use. The relevant data available in the literature suggest that a weaker compliance, poorer therapy response and higher sensitivity for extrapyramidal side effects are key features of schizophrenia and comorbid cannabis use disorder and represent a clinical challenge. Because of paucity of available research in the field there is not enough evidence to clearly depict the exact psychopharmacological profile of cannabis related schizophrenia. Further investigations are needed to assess phenotypic characteristics of this entity and to tailor effective treatment options accordingly.

AB - Although cannabis use disorder is strongly related to schizophrenia and treatment of patients with double diagnosis provides serious problem, specific pharmacological, molecular and therapeutical data on this subgroup are poorly available. In this paper we present a critical review on psychopharmacological boundaries of schizophrenia with concurrent cannabis use. The relevant data available in the literature suggest that a weaker compliance, poorer therapy response and higher sensitivity for extrapyramidal side effects are key features of schizophrenia and comorbid cannabis use disorder and represent a clinical challenge. Because of paucity of available research in the field there is not enough evidence to clearly depict the exact psychopharmacological profile of cannabis related schizophrenia. Further investigations are needed to assess phenotypic characteristics of this entity and to tailor effective treatment options accordingly.

UR - http://www.scopus.com/inward/record.url?scp=84875533616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875533616&partnerID=8YFLogxK

M3 - Article

C2 - 22716145

AN - SCOPUS:84875533616

VL - 18

SP - 4890

EP - 4896

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 32

ER -